116313-86-1

Basic information

• Product Name: 3,4-dihydroxy-5-nitro-benzonitrile
• Synonyms: 3,4-dihydroxy-5-nitro-benzonitrile
• CAS NO: 116313-86-1
• Molecular Formula: C₇H₄N₂O₄
• Molecular Weight: 180.12
• Mol File: 116313-86-1.mol

Chemical Properties

• Boiling Point: 327.8°C at 760 mmHg
• Flash Point: 152.1°C
• Appearance: /
• Density: 1.69g/cm³
• Vapor Pressure: 0.000103mmHg at 25°C
• Refractive Index: 1.683
• CAS DataBase Reference: 3,4-dihydroxy-5-nitro-benzonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3,4-dihydroxy-5-nitro-benzonitrile(116313-86-1)
• EPA Substance Registry System: 3,4-dihydroxy-5-nitro-benzonitrile(116313-86-1)

Safety Data

• Hazardous Substances Data: 116313-86-1(Hazardous Substances Data)

Usage

Synthesis Reference(s)

Journal of Medicinal Chemistry, 32, p. 841, 1989 DOI: 10.1021/jm00124a017

InChI:InChI=1/C7H4N2O4/c8-3-4-1-5(9(12)13)7(11)6(10)2-4/h1-2,10-11H

Upstream product

• 116313-85-0 3,4-dihydroxy-5-nitrobenzaldehyde 
• 2950-43-8 hydroxylamine-O-sulfonic acid 

Downstream Products

• 134611-66-8 3,4-dihydroxy-5-nitrobenzamide 
• 180031-16-7 4-chloro-3-hydroxy-5-nitro-benzonitrile 

Relevant articles and documents

Synthesis of 7-substituted-(2,3-dihydro-1,4-benzodioxin-5-yl)-piperazine

A simple and versatile method for the synthesis of 7-substituted (2,3-dihydro-1,4-benzodioxin-5-yl)-piperazines starting from easy available class of derivatives has been developed. Copyright Taylor & Francis Group, LLC.

Catechol derivatives

Catechol derivatives of the formula STR1 wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adensoylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuornal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure. Formula Ia above embraces not only compounds which form part of the invention, but also known compounds; the compounds which form part of the invention can be prepared according to known methods.

PHARMACOLOGICALLY ACTIVE COMPOUNDS, METHODS FOR THE PREPARATION THEREOF AND COMPOSITIONS CONTAINING THE SAME

Pharmacologically active catechol derivatives of formula I I wherein R1 and R2 independently comprise hydrogen, alkyl, acyl, optionally substituted aroyl, lower alkylsulfonyl or alkylcabamoyl or taken together form a lower alkylidene or cycloalkylidene, X comprises an electronegative substituent such as halogen, nitro, cyano, lower alkylsulfonyl, sulfonamido, aldehyde, caboxyl or trifluoromethyl and R3 comprises hydrogen, halogen, hydroxy alkyl, amino, nitro, cyano, trifluoromethyl, lower alkylsulfonyl, sulfonamide, aldehyde, alkyl carbonyl, aralkylidene carbonyl or carboxyl or a group selected from wherein R4 comprises hydrogen, alkyl, cyano, carboxyl or acyl and R5 comprises hydrogen, cyano, carboxyl, alkoxycarbonyl, carboxyalkenyl, nitro, acyl, optionally substituted aroyl or heteroaroyl, hydroxyalkyl or carboxyalkyl or R4 and R5 together form a five to seven membered substituted cycloalkanone ring; -(CO)n(CH2)m-COR wherein n is 0-1 and m is 0-7 and R comprises hydroxy, alkyl, carboxyalkyl, optionally substituted alkene, alkoxy or optionally substituted amino; wherein R8 and R9 independently comprise hydrogen or one of the following optionally substituted groups; alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, or together form an optionally substituted piperidyl group; -NH-CO-R10 wherein R10 comprises a substituted alkyl group

Synthesis of Some Novel Potent and Selective Catechol O-Methyltransferase Inhibitors

A series of disubstituted catechol derivatives was synthesized and tested as potential COMT inhibitors.The most active compounds were more than 1000 times more potent (IC 50 = 3-6 nM) in vitro than the known COMT inhibitor, 3',4'-dihydroxy-2-methylpropiop